Surgical success 2 years after preserflo microshunt implantation: real world data from a single eye care centre.

Purpose: To evaluate real world efficacy and safety of the Preserflo MicroShunt (PM) in a heterogenous patient cohort at a single tertiary eye care centre.A retrospective data analysis of PM implantations between 2019 and 2022 was performed. Primary outcome measures were complete-, qualified-, and overall- success as well as failure defined according to the WGA criteria. Secondary outcomes were intraocular pressure (IOP) and IOP lowering medications.38 patients were included in the study. After 24 months, complete success was achieved in 31.58% and qualified success in 28.95% whereas 39.47% were classified as failure. IOP was reduced by 55.2% from mean 25.57 ± 10.03 mmHg at baseline to 11.45 ± 3.37 mmHg two years postoperative in eyes classified as success. The number of IOP lowering medications was reduced from 2.73 ± 1.33 before surgery to 1.14 ± 1.31 at the end of the follow-up period.Two years postoperatively an overall success rate of 60.53% was achieved and a significant IOP reduction was preserved over the complete two years follow-up time.<bold><italic>What is known</italic></bold>Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. <bold><italic>What is new</italic></bold>Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Patients and methods: To evaluate real world efficacy and safety of the Preserflo MicroShunt (PM) in a heterogenous patient cohort at a single tertiary eye care centre.A retrospective data analysis of PM implantations between 2019 and 2022 was performed. Primary outcome measures were complete-, qualified-, and overall- success as well as failure defined according to the WGA criteria. Secondary outcomes were intraocular pressure (IOP) and IOP lowering medications.38 patients were included in the study. After 24 months, complete success was achieved in 31.58% and qualified success in 28.95% whereas 39.47% were classified as failure. IOP was reduced by 55.2% from mean 25.57 ± 10.03 mmHg at baseline to 11.45 ± 3.37 mmHg two years postoperative in eyes classified as success. The number of IOP lowering medications was reduced from 2.73 ± 1.33 before surgery to 1.14 ± 1.31 at the end of the follow-up period.Two years postoperatively an overall success rate of 60.53% was achieved and a significant IOP reduction was preserved over the complete two years follow-up time.<bold><italic>What is known</italic></bold>Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. <bold><italic>What is new</italic></bold>Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Result: To evaluate real world efficacy and safety of the Preserflo MicroShunt (PM) in a heterogenous patient cohort at a single tertiary eye care centre.A retrospective data analysis of PM implantations between 2019 and 2022 was performed. Primary outcome measures were complete-, qualified-, and overall- success as well as failure defined according to the WGA criteria. Secondary outcomes were intraocular pressure (IOP) and IOP lowering medications.38 patients were included in the study. After 24 months, complete success was achieved in 31.58% and qualified success in 28.95% whereas 39.47% were classified as failure. IOP was reduced by 55.2% from mean 25.57 ± 10.03 mmHg at baseline to 11.45 ± 3.37 mmHg two years postoperative in eyes classified as success. The number of IOP lowering medications was reduced from 2.73 ± 1.33 before surgery to 1.14 ± 1.31 at the end of the follow-up period.Two years postoperatively an overall success rate of 60.53% was achieved and a significant IOP reduction was preserved over the complete two years follow-up time.<bold><italic>What is known</italic></bold>Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. <bold><italic>What is new</italic></bold>Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Conclusion: To evaluate real world efficacy and safety of the Preserflo MicroShunt (PM) in a heterogenous patient cohort at a single tertiary eye care centre.A retrospective data analysis of PM implantations between 2019 and 2022 was performed. Primary outcome measures were complete-, qualified-, and overall- success as well as failure defined according to the WGA criteria. Secondary outcomes were intraocular pressure (IOP) and IOP lowering medications.38 patients were included in the study. After 24 months, complete success was achieved in 31.58% and qualified success in 28.95% whereas 39.47% were classified as failure. IOP was reduced by 55.2% from mean 25.57 ± 10.03 mmHg at baseline to 11.45 ± 3.37 mmHg two years postoperative in eyes classified as success. The number of IOP lowering medications was reduced from 2.73 ± 1.33 before surgery to 1.14 ± 1.31 at the end of the follow-up period.Two years postoperatively an overall success rate of 60.53% was achieved and a significant IOP reduction was preserved over the complete two years follow-up time.<bold><italic>What is known</italic></bold>Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. <bold><italic>What is new</italic></bold>Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Key Messages: To evaluate real world efficacy and safety of the Preserflo MicroShunt (PM) in a heterogenous patient cohort at a single tertiary eye care centre.A retrospective data analysis of PM implantations between 2019 and 2022 was performed. Primary outcome measures were complete-, qualified-, and overall- success as well as failure defined according to the WGA criteria. Secondary outcomes were intraocular pressure (IOP) and IOP lowering medications.38 patients were included in the study. After 24 months, complete success was achieved in 31.58% and qualified success in 28.95% whereas 39.47% were classified as failure. IOP was reduced by 55.2% from mean 25.57 ± 10.03 mmHg at baseline to 11.45 ± 3.37 mmHg two years postoperative in eyes classified as success. The number of IOP lowering medications was reduced from 2.73 ± 1.33 before surgery to 1.14 ± 1.31 at the end of the follow-up period.Two years postoperatively an overall success rate of 60.53% was achieved and a significant IOP reduction was preserved over the complete two years follow-up time.<bold><italic>What is known</italic></bold>Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. Multiple studies have proven that the Preserflo MicroShunt is a safe and efficient surgical procedure to lower intraocular pressure.The success rates reported for primary open angle glaucoma are comparable to trabeculectomy. <bold><italic>What is new</italic></bold>Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period.Real world data including different glaucoma subtypes at one tertiary care centre are reported with a two-year follow up.An overall surgical success rate of 60.53% was achieved.An intraocular pressure reduction of 50.2% was sustained over the two years follow up period. [ABSTRACT FROM AUTHOR]